PERRIGO COMPANY PLC (PRGO) Stock Price

PRGOStock

$16.63−22.76%52W

Market Cap$2.31B

P/E—

PEG Ratio1.14

Div yield3.54%

Beta0.69

PRGO Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)35.08%

Price vs S&P 500 (4W)19.02%

PEG Ratio1.14

VGM Score61.85

Indicated Dividend Yield (Annual)3.54%

P/CF (Annual)9.68x

Book Value / Share (Quarterly)$18.14

P/TBV (Annual)3.31x

Indicated Dividend (Annual)$1.16

Revenue Growth (3Y)-1.51%

Cash Flow / Share (Quarterly)$0.86

Payout Ratio (TTM)97.80%

Price vs S&P 500 (YTD)7.54%

Gross Margin (TTM)33.26%

Net Profit Margin (TTM)-41.85%

EPS (TTM)$-12.59

10-Day Avg Trading Volume2.71M

EPS Excl Extra (TTM)$-12.59

Revenue Growth (5Y)0.79%

EPS (Annual)$-10.29

Dividend / Share (Annual)$1.16

ROI (Annual)-21.68%

Gross Margin (Annual)35.14%

Net Profit Margin (5Y Avg)-8.51%

Cash / Share (Quarterly)$2.88

Revenue Growth QoQ (YoY)-3.17%

ROA (Last FY)-16.70%

Revenue Growth TTM (YoY)-4.19%

EBITD / Share (TTM)$-8.76

ROE (5Y Avg)-11.41%

Operating Margin (TTM)-37.75%

Cash Flow / Share (Annual)$1.05

P/B Ratio0.92x

P/B Ratio (Quarterly)0.55x

Net Income / Employee (Annual)$-176,000

EV / Revenue (TTM)1.26x

Net Interest Coverage (TTM)-6.98x

ROA (TTM)-20.28%

EV / EBITDA (TTM)8.54x

EPS Incl Extra (Annual)$-10.29

Current Ratio (Annual)2.76x

Quick Ratio (Quarterly)1.09x

3-Month Avg Trading Volume3.18M

52-Week Price Return-22.76%

EV / Free Cash Flow (Annual)35.86x

Revenue / Employee (TTM)$511,700

Tangible BV / Share (Quarterly)$1.70

P/S Ratio (Annual)0.54x

Asset Turnover (Annual)0.50x

52-Week High$22.02

Operating Margin (5Y Avg)-1.99%

EPS Excl Extra (Annual)$-10.29

CapEx CAGR (5Y)-14.60%

Tangible BV CAGR (5Y)-26.39%

26-Week Price Return44.99%

Quick Ratio (Annual)1.44x

13-Week Price Return55.13%

Total Debt / Equity (Annual)1.24x

Current Ratio (Quarterly)2.32x

Enterprise Value$5.20B

Revenue / Share Growth (5Y)0.44%

Asset Turnover (TTM)0.48x

Book Value / Share Growth (5Y)-12.88%

Revenue / Employee (Annual)$525,100

Inventory Turnover (Annual)2.47x

Pretax Margin (Annual)-30.52%

Cash / Share (Annual)$3.86

3-Month Return Std Dev62.22%

Gross Margin (5Y Avg)34.68%

Net Income / Employee (TTM)$-214,200

EBITDA CAGR (5Y)-8.13%

EBITDA Interim CAGR (5Y)-3.50%

ROE (Last FY)-48.56%

Net Interest Coverage (Annual)-8.84x

EPS Basic Excl Extra (Annual)$-10.29

P/FCF (TTM)9.35x

Receivables Turnover (TTM)5.69x

EV / Free Cash Flow (TTM)43.61x

Total Debt / Equity (Quarterly)1.31x

EPS Incl Extra (TTM)$-12.59

Receivables Turnover (Annual)6.37x

ROI (TTM)-26.08%

Dividend Growth Rate (5Y)4.76%

P/S Ratio (TTM)0.56x

Pretax Margin (5Y Avg)-5.88%

Revenue / Share (Annual)$30.71

Tangible BV / Share (Annual)$4.21

Forward P/E6.09x

Free OCF CAGR (5Y)-19.55%

Price vs S&P 500 (52W)-38.29%

Year-to-Date Return19.47%

5-Day Price Return7.64%

EPS Normalized (Annual)$-10.29

ROA (5Y Avg)-4.11%

Net Profit Margin (Annual)-33.51%

Month-to-Date Return12.67%

Cash Flow / Share (TTM)$2.81

EBITD / Share (Annual)$-5.91

Operating Margin (Annual)-27.18%

LT Debt / Equity (Annual)1.22x

P/CF (TTM)11.77x

ROI (5Y Avg)-5.27%

LT Debt / Equity (Quarterly)1.30x

EPS Basic Excl Extra (TTM)$-12.59

P/TBV (Quarterly)5.70x

P/B Ratio (Annual)0.65x

Dividend / Share (TTM)$1.16

Inventory Turnover (TTM)2.43x

Pretax Margin (TTM)-38.90%

Book Value / Share (Annual)$21.33

Price vs S&P 500 (13W)52.45%

Dividend Yield (TTM)6.93%

Beta0.69x

P/FCF (Annual)15.90x

Revenue / Share (TTM)$29.69

ROE (TTM)-55.97%

52-Week Low$9.22

vGradeB

gGradeD

mGradeA

vgmGradeB

PRGO Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 5, 2026	$0.35	$0.50	+40.85%(+$0.15)
Q1 2026	May 6, 2026	$0.31	$0.43	+40.17%(+$0.12)
Q4 2025	Feb 26, 2026	$0.78	$0.77	-1.28%(-$0.01)
Q3 2025	Nov 5, 2025	$0.77	$0.80	+3.91%(+$0.03)
Q2 2025	Aug 6, 2025	$0.59	$0.57	-4.02%(-$0.02)

PRGO Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

3.80

Industry Peers — Pharmaceuticals(574)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
PRGOPERRIGO COMPANY PLC	B	D	A	0.6x	-4.2%	33.3%	—	$16.63
LLYEli Lilly & Co.	D	B	A	14.9x	49.6%	83.4%	27.6%	$1257.03
JNJJohnson & Johnson	D	C	B	6.2x	7.8%	67.7%	14.9%	$255.56
ABBVABBVIE INC.	D	C	A	7.8x	10.4%	72.8%	-2.9%	$285.42
MRKMerck & Co., Inc.	D	C	A	5.4x	4.6%	77.3%	21.2%	$145.95
NVSNovartis AG	C	C	B	4.9x	3.3%	75.0%	15.3%	$150.62
AZNAstraZeneca PLC	C	B	B	4.3x	8.6%	81.3%	21.9%	$165.41
ABTAbbott Laboratories	C	C	B	3.9x	8.1%	56.8%	8.2%	$104.89
NVONovo-Nordisk A/S	B	C	C	3.5x	5.6%	80.7%	20.7%	$38.83
PFEPfizer Inc.	C	D	A	2.6x	-0.2%	74.7%	-3.5%	$29.58
VRTXVertex Pharmaceuticals Inc	D	C	B	10.1x	10.2%	86.0%	8.3%	$499.74
BMYBristol-Myers Squibb Co.	B	B	B	2.5x	3.1%	71.7%	—	$59.75
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	C	C	B	2.3x	5.0%	73.6%	-0.5%	$49.51
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	D	B	1.8x	13.4%	72.8%	-8.2%	$40.61
REGNRegeneron Pharmaceuticals Inc	C	C	A	5.2x	9.3%	86.0%	6.3%	$790.74
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	A	2.1x	3.1%	65.5%	-12.6%	$19.67
TEVATeva Pharmaceutical Industries Limited	D	C	A	2.8x	4.1%	52.9%	—	$41.50
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	6.3x	31.1%	88.5%	—	$369.06
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	A	13.8x	10.0%	—	-12.1%	$60.96
ZTSZOETIS INC.	C	C	B	3.5x	1.4%	71.6%	12.0%	$79.38
ALNYAlnylam Pharmaceuticals, Inc.	D	A	C	6.5x	95.1%	79.7%	—	$231.83
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	3215.5x	-67.6%	81.2%	—	$33.53
UTHRUnited Therapeutics Corp	C	C	B	7.2x	2.5%	86.1%	19.3%	$533.12
GMABGenmab A/S ADS	D	C	A	5.5x	22.3%	93.0%	6.8%	$37.00
VTRSViatris Inc. Common Stock	B	C	A	1.5x	4.4%	40.3%	—	$18.66
INSMInsmed, Inc.	F	A	C	18.5x	185.8%	83.5%	—	$96.27
ASNDAscendis Pharma A/S Ordinary Share	D	A	B	11.9x	113.3%	91.3%	—	$225.25
JAZZJazz Pharmaceuticals, Inc.	B	C	B	3.0x	12.6%	88.4%	-1.4%	$210.23
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	18.2x	202.4%	94.4%	—	$66.39
CORTCorcept Therapeutics Inc.	F	C	A	14.3x	16.0%	98.3%	-0.5%	$110.16
ELANElanco Animal Health Incorporated Common Stock	D	B	B	2.3x	11.9%	55.4%	29.9%	$23.55
SMMTSummit Therapeutics Inc. Common Stock	F	—	C	12187.5x	—	—	—	$14.63
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	C	B	3.1x	-0.9%	61.4%	16.5%	$13.07
BMRNBioMarin Pharmaceuticals Inc	C	C	B	3.1x	11.2%	79.6%	-17.0%	$54.68
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	8.1x	149.0%	91.5%	—	$449.74
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	213.8x	2928.4%	—	—	$84.95
CYTKCytokinetics Inc.	F	D	B	127.3x	-21.1%	—	—	$61.95
PTGXProtagonist Therapeutics, Inc	F	B	B	29.5x	34.8%	—	—	$128.75
TGTXTG Therapeutics, Inc.	D	B	B	10.3x	76.1%	82.4%	—	$53.97
AXSMAxsome Therapeutics, Inc	D	B	C	10.6x	56.9%	93.2%	—	$157.14
ARWRArrowhead Research Corporation	D	A	C	11.8x	16.9%	—	—	$55.90
ABVXAbivax SA American Depositary Shares	—	—	C	—	—	—	—	$88.13
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	5995.2x	—	—	—	$79.90
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	8.2x	-7.5%	98.2%	—	$42.94
ALKSAlkermes Inc. plc	D	C	B	4.1x	10.8%	84.6%	—	$41.22
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	789.2x	—	—	—	$241.76
AMRXAmneal Pharmaceuticals, Inc. Class A Common Stock	D	C	A	2.0x	9.3%	39.3%	-18.4%	$19.18
KNSAKiniksa Pharmaceuticals International, plc Class A Ordinary Shares	D	B	A	7.3x	58.9%	89.8%	—	$78.59
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	24.7x	53.5%	70.9%	—	$86.17
LGNDLigand Pharmaceuticals Inc.	D	B	B	20.3x	54.9%	95.4%	—	$295.54
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	—	—	—	—	$142.78

About PERRIGO COMPANY PLC

Perrigo is a global consumer health company specializing in self-care products. Its North American business, representing approximately two-thirds of sales, operates as a major private-label supplier to retailers including Walmart, Amazon, Costco, and CVS. Internationally, it markets branded products—including Compeed, Solpadeine, Coldrex, and ellaOne—in Europe, Australia, and select Asian markets. The dual strategy balances high-volume private-label revenue with branded product margins.

PRGO Next Earnings Report

Report dateNov 4, 2026

QuarterQ3 2026

Report timeBMO

EPS estimate$0.53

Revenue estimate$999.15M

Also reporting on Nov 4, 2026

Scheduled date with consensus estimates — both can change before the company reports.

Earnings calendar for November 2026

Companies in Related Industries

NGVTIngevity CorporationChemicals
ADMAADMA Biologics, Inc.Biological Products
IOSPInnospec Inc.Chemicals
ROGRogers CorporationPlastics & Resins
CLDXCelldex Therapeutics, IncIn Vitro Diagnostics
VCELVericel CorporationBiological Products
BCRXBioCryst Pharmaceuticals IncBiological Products
MTXMinerals Technologies IncIndustrial Chemicals

Same SIC sector, outside this company's own industry.

Analyst Sentiment

3.8

Buy

Consensus rating

52-Week Range

Low$9.22

High$22.02